Abstract: A scleral lens with a fenestration and pockets. One fenestration or a plurality of annularly-distributed fenestrations are provided in an optic zone of the scleral lens; and two or more pockets are provided in a pocket annular zone on a posterior surface of the optic zone. The pockets are configured to trap gas bubbles near the fenestration, where the fenestration is located radially outward from the pocket annular zone and not located in a transition zone of the scleral lens, and the transition zone is configured to be located above the limbus of the eyeball during wearing of the scleral lens. The lens of the present invention will not be adsorbed to the cornea and can be worn comfortably and maintain clear visual acuity for up to 12 hours.

Abstract: The present invention provides a scleral lens with a fenestration and pockets. One fenestration or a plurality of annularly-distributed fenestrations are provided in an optic zone of the scleral lens; and two or more pockets are provided in a pocket annular zone on a posterior surface of the optic zone. The pockets are configured to trap gas bubbles near the fenestration, where the fenestration is located radially outward from the pocket annular zone and not located in a transition zone of the scleral lens, and the transition zone is configured to be located above the limbus of the eyeball during wearing of the scleral lens. The lens of the present invention will not be adsorbed to the cornea, and can be worn comfortably and maintain clear visual acuity for up to 12 hours.

Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

Abstract: The present invention provides a scleral lens with a fenestration and pockets. One fenestration or a plurality of annularly-distributed fenestrations are provided in an optic zone of the scleral lens; and two or more pockets are provided in a pocket annular zone on a posterior surface of the optic zone. The pockets are configured to trap gas bubbles near the fenestration, where the fenestration is located radially outward from the pocket annular zone and not located in a transition zone of the scleral lens, and the transition zone is configured to be located above the limbus of the eyeball during wearing of the scleral lens. The lens of the present invention will not be adsorbed to the cornea, and can be worn comfortably and maintain clear visual acuity for up to 12 hours.

Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.